Real-World Integration

The goal of this study was to measure Canvas Dx performance in real-world settings through analysis of early post-market authorization prescription and output data.

Table 6: Real-world evidence study

Year/s	Methods	Participants	Key Findings	Reference
2021–2022	A de-identified aggregate data analysis of the initial 124 Canvas Dx prescriptions fulfilled post-market authorization.	The first 124 real-world Canvas Dx users Prescriptions were generated from 15 states. Children had a median age of 39.6 months, were 27.4% female, and had a 51.6% autism prevalence rate.	Compared to the clinical reference standard, Canvas Dx had a NPV of 95.2% (20/21, 95% CI [76.2%, 99.9%]) and PPV of 94.4% (51/54, 95% CI [84.6%, 98.8%]) with 60.5% (75/124, 95% CI [51.3%, 69.1%]) receiving a determinate (positive or negative for autism) result. The median age of children who received a positive output was 35.5 months: this is over 1 year earlier than the current median age of autism diagnosis in the U.S.	Kraft. et al. An Aggregate and Deidentified Analysis of Real-World Performance of an Artificial Intelligence-based Diagnosis Aid for Autism Spectrum Disorder. Presented at PAS (Poster presentation) (2023).